Bleomycin-induced lung injury is an established murine model of human pulmonary fibrosis. Although procoagulant molecules (e.g., tissue factor [TF]) and fibrinolytic components (e.g., urokinase [u-PA] and type 1 plasminogen activator inhibitor [PAI-1]) have been detected in alveolar fluid from injured lungs, the origin of these molecules remains unknown. We therefore examined the expression of procoagulant and fibrinolytic components in relation to the distribution of parenchymal fibrin in bleomycin-injured lungs. Extravascular fibrin localized to the alveolar and extracellular matrix in injured lung tissue. Injured lung tissue extracts contained elevated levels of PAI-i activity and decreased levels of u-PA activity. Whole lung PAT-i and TF mRNAs were dramatically induced by lung injury. In situ hybridization of injured lungs revealed that PAI-1, u-PA, and TF mRNAs were induced within the fibrin-rich fibroproliferative lesions, primarily in fibroblast-like and macrophagelike cells, respectively, while TF mRNA was also induced in perilesional alveolar cells. Taken together, these observations suggest that the induction of PAT-i and TF gene expression plays an important role in the formation and persistence of extracellular fibrin in bleomycin injured murine lungs. (J. Clin. Invest. 1995. 96:1621-1630
Introduction
Bleomycin-induced lung injury in animals is a well established histological and biochemical model of human pulmonary fibro-sis (1) (2) (3) . In strain-sensitive mice, a single intratracheal (IT)' instillation of bleomycin results in a neutrophilic and lymphocytic acute pan-alveolitis in the first week (4). These changes are followed by the clearing of the alveolar inflammatory cells, with subsequent fibroblast proliferation and the synthesis of extracellular matrix protein eventually leading to peribronchial pulmonary fibrosis (5, 6) . The evolution of these fibroproliferative lesions occurs within 3 wk of the instillation of bleomycin.
Current concepts about the nature of the resolution process that takes place 2-3 wk after bleomycin-induced lung injury suggest that the final outcome depends on the severity and the protraction of the early injury (1, 2) . Furthermore, it has been suggested that the tissue repair process occurs along an insoluble matrix composed of fibrin and both plasma-derived and cellsynthesized matrix proteins (7, 8) . This matrix-bound fibrin and its soluble degradation products may, in turn, modulate the tissue repair response by altering vascular tone, stimulating fibroblast and neutrophil migration, and enhancing adhesion and spreading of both endothelial cells and fibroblasts (9) (10) (11) (12) . Moreover, in the fibrinous exudate that forms after acute lung injury, other fibrin-bound glycoproteins (e.g., fibronectin) may act as potent matrix secretogogue(s) for fibroblasts (13) , thereby altering the final extent of fibrosis. These concepts gain additional support by the recent demonstration of fibrin in the alveolar lining of lung biopsy tissue from patients with idiopathic pulmonary fibrosis (14) . Taken together, these observations emphasize the need to identify the factor(s) responsible for fibrin deposition and clearance after lung injury.
Tissue factor (TF) is the primary cellular initiator of the coagulation protease cascades (15) . High-affinity binding of factors Vil/Vila to TF activates factors IX and X by limited proteolysis (16). Studies of bronchoalveolar lavage fluid suggest that TF functions as the initiator of the coagulation cascade in the alveolar space as well (17) . In addition to procoagulant activity, normal alveolar fluid possesses measurable fibrinolytic activity ( 18) . The process of fibrinolysis in the alveolar space is generally thought to be regulated primarily at the level of the activation of this system by plasminogen activators (PA) s, as plasminogen is ubiquitous in lung tissue (19) . The major PA responsible for this action in many extravascular tissues is urokinase (u-PA), although tissue type PA (t-PA) may also be present (20, 21) . These PAs can be specifically inhibited by type 1 plasminogen activator inhibitor (PAI-1), a 50-kD glycoprotein that is a member of the serpin superfamily of genes (22) .
The potential relevance of the PA/PAI-1 system to extracellular matrix remodeling after lung injury is underscored by its highly regulated expression in diverse tissue remodeling processes such as ovulation, breast gland involution, and embryogenesis (23) . Moreover, recent reports from our laboratory have described alterations in the levels of pulmonary TF and PAI-1 mRNAs after gram-negative bacterial endotoxin induced lung injury in mice (24, 25) .
Within 1 wk after IT bleomycin in the rat, bronchoalveolar lavage fluid TF activity is enhanced, while u-PA-mediated fibrinolytic activity is inhibited, in part, by increases in PAI-1 (26) . These observations suggest that the extent of extravascular fibrin deposition during lung injury may reflect the balance of the actions of TF and the various components of the fibrinolytic system on plasma-derived fibrinogen (27) . However, the origins of the TF and PAI-I found in bronchoalveolar lavage fluid are unknown, and the lavage procedure itself may cause the fragmentation and release of TF-containing plasma membrane vesicles from alveolar cells thereby complicating extrapolation to the tissue level (17) . Little is known regarding the localization of fibrin to fibroproliferative phase (i.e., 14 and 21 d) lesions, or about the tissue level expression of TF, u-PA, t-PA, and PAI-I in bleomycin-injured lungs, despite the alveolar fluid findings. In this report, we characterize the origin and potential role of TF, PAI-1, and the PAs in the repair process that follows bleomycin-induced lung injury in mice. Pulmonary TF and PAI-1 mRNAs were found to be specifically induced within fibrinrich fibroproliferative lesions suggesting an important role for fibrin persistence in the formation of these lesions. Pulmonary u-PA activity localized to the parenchyma and u-PA mRNA induction localized to fibroproliferative lesions, however, pulmonary u-PA activity was found to be suppressed in association with an enhanced PAIT-activity. Immunohistochemical analysis. Immunohistochemical analysis was performed by minor modifications of the commercially available indirect avidin-biotin-peroxidase procedure (Zymed Laboratories, Inc., S. San Francisco, CA) as described previously (33) . Briefly, the tissue was deparaffinized in xylene, rehydrated, and incubated in 3% H202 in methanol to inhibit endogenous peroxidase activity. After additional blocking with 10% heat inactivated goat serum, the primary antibody was applied and the tissue was incubated overnight at 40C. After incubation, the biotin-tagged secondary IgG and streptavidin-peroxidase complex were sequentially applied to the tissue sections for 30 min. The antigen was visualized (i.e., by aminoethylcarbazole) as a red precipitate surrounded by a blue hematoxylin counterstain with bright field microscopy. Immunostaining of the same tissue with preimmune rabbit IgG was performed in parallel as a negative control. The polyclonal rabbit antisera directed toward murine fibrinogen identifies fibrin and all three chains of fibrinogen. All positive staining with this antibody is herein referred to as fibrin based on confirmatory electron microscopic surveys of glutaraldehyde-fixed lung tissue.
Methods
Direct and reversefibrin autography. Direct and reverse fibrin autography was performed on lung tissue extracts after nonreducing SDS-PAGE, as previously described (34, 35) , and on frozen lung tissue sections (21). The lung tissue was removed from exsanguinated mice, finely minced, exhaustively washed in 40C phosphate buffered saline, and snap-frozen in liquid nitrogen. Lung protein extracts were prepared by homogenization of lung tissue in 10 vol (wt/vol) of 1% SDS. Preliminary experiments revealed no differences in the extraction of PAs and PAI-I by either 1% SDS or buffered 0.1 M KSCN (36) . Equivalent volumes per lane were loaded on the SDS-polyacrylamide gel. For lung tissue sections, the overlay gel technique was adapted for use on 10-qm frozen tissue sections based on a prior method used on human tissue (37) . An agarose gel (final concentration, 0.83%, Sea Plaque; FMC Bioproducts, Rockland, ME) containing purified human plasminogen (final concentration, 8.3 ,g/ml), bovine fibrinogen (final concentration, 8 mg/ml; Sigma Chemical Co.) and alpha-thrombin (final concentration, 0.5 U/ml, kindly provided by Dr. J. Fenton, New York State Dept. of Health, Albany, NY) was cast at a thickness of 0.5 mm and placed on prewarmed tissue sections. The sections and overlay gel were incubated at 37°C for 1-2 h in a humidified chamber at which time they were photographed under indirect light. Preliminary experiments using this system revealed that amiloride (final concentration, 1 mM; Sigma Chemical Co.) (38) Northern blot analysis. Tissues destined for RNA extraction were harvested by dissection, finely minced, washed extensively with cold phosphate buffered saline, and snap-frozen in liquid nitrogen. Whole tissue RNA was extracted by the acid guanidium isothiocyanate-phenol chloroform method (39) , and the concentration of total RNA was deter- (24, 40 with intensifier screens on XAR-5 film (Eastman Kodak Co., Rochester, NY). The intensity of the signal for specific mRNAs was quantified directly by using a radioanalytic image processor (AMBIS), and the signal from a specific mRNA species was normalized to the signal intensity for the 18S ribosomal RNA as described (24) . In preliminary experiments, we confirmed the work of Hoyt et al., who showed an increase in the proportion of mRNA/total RNA in bleomycin-injured lungs (42) , by demonstrating a two-fold increase in the signal for the two constitutively produced mRNAs (i.e., glyceraldehyde-3-phosphate dehydrogenase [G3PDH] and CHO:B [43] ) in total RNA extracts of lungs injured by bleomycin 8 and 14 d earlier.
In situ hybridization. The radiolabeled probes used for these studies were prepared as described (40) . Briefly, radiolabeled sense and antisense RNA were generated by in vitro transcription using SP6 1C) and fibrin was not detected in the lung parenchyma of control animals that received IT saline (Fig. 1D ).
The effects of bleomycin on the fibrinolytic components in Figure 4 . Localization of TF mRNA in lung tissue from animals exposed to bleomycin. Fixed (Fig. 2 A) . The identity of these zones as t-PA and u-PA was verified by their selective inhibition with t-PA antibodies (10 jig/ml) and amiloride, respectively, in the overlay gel (data not shown). Panel B shows that lung PAI-I activity was dramatically increased in bleomycin injured lungs over the entire 21-d period tested (Fig.  2 B, lane 2) . This inhibitor comigrated with murine PAI-I from phorbol myristate acetate-stimulated 3T3 cells (Fig. 2 B , lane 3) (33) . When frozen lung tissue sections from animals exposed to saline were incubated under fibrin gels, fibrinolytic activity was detected over vascular structures (Fig. 3, A and B) . These structures were identified based on their immediate peribronchial location, relative size, and their positive staining with antibodies to vWF (data not shown). The vascular proteolytic activity is related to t-PA since it is selectively inhibited by antibodies against this molecule (Fig. 3 C) . Furthermore, t-PA antigen colocalized immunohistochemically to vWF-positive endothelial cells within these structures (data not shown). No u-PA activity was detected by the basic gel overlay method. This lack of u-PA activity could be due to the ability of the thrombin in the overlay gel to irreversibly inactivate single chain u-PA (45) . We therefore repeated the experiments using fibrin gels that were incubated before use with a fivefold molar excess of hirudin, an active site inhibitor of thrombin. Using this approach, we were now able to detect generalized lung parenchymal fibrinolytic activity (i.e., dark areas; Fig. 3 E) that was not obvious in the absence of hirudin. This activity was not affected by antibodies to t-PA but was inhibited by amiloride (Fig. 3 F) uncharacterized intravascular inhibitors. To quantitate and determine the localization of these molecules in relation to lesional tissue in bleomycin-injured lungs, Northern blotting and in situ hybridization for these molecules were performed (see below). Induction of fibrinolytic and procoagulant mRNA species by bleomycin. The time course of bleomycin-related induction of lung PAM-, TF, u-PA, and t-PA mRNAs were determined by Northern blot analysis of whole lung RNA. The steady state levels of each of these specific mRNAs increased by 4 d after bleomycin lung injury, peaked at 8-14 d, when compared to the saline-instilled lungs, and declined towards baseline by 21 d after IT bleomycin (Table I) . However, the induction of TF and PAI-I mRNAs was quantitatively greater than that observed for the PAs. The total RNA content of these tissues also increased threefold during the same time, indicating that the absolute increase in the mRNAs for TF and PAM-was -15-fold. Neither the intensity of the signals for the specific mRNAs nor the total pulmonary RNA content varied in the saline-instilled mice over this time frame (Table I) .
Analysis oflung tissue by in situ hybridization. To determine the cellular origin and localization of the induced mRNAs relative to lesional areas, in situ hybridization was performed on lung tissue from saline and bleomycin-exposed animals. Bleomycin lung injury resulted in a strong increase in the proportion of TF mRNA expressing cells in both normal and alveolitis (Fig. 4 and 6 ). During the fibroproliferative phase ( 14 d after bleomycin), the proportion of TF mRNA expressing cells increased only within the lesional areas (to 28±4.9% of cells positive; P < 0.0001) over that of salineinstilled controls (Figs. 4 and 6 ). TF mRNA expression was also noted in the major bronchial epithelial cell layer in normal and bleomycin-injured lungs (data not shown).
In contrast, PAI-I-expressing cells were induced relative to saline controls, but specifically within involved areas of lung at both the alveolitis phase (2.9+0.8% cells positive from saline vs 19.6+2.5% cells positive in alveolitis areas; P < 0.01) and at the fibroproliferative lesional phase (53±20% cells positive within lesion; P < 0.0001 vs saline) (Fig. 5 A; Fig. 6 ). In contrast to the focal induction of PAI-1 mRNA in specific lesional cells, a constitutively expressed mRNA (i.e., G3PDH) did not localize to specific cells or within the fibroproliferative lesions in injured lungs (Fig. 5 B) . Sense transcript controls from the same tissue that were hybridized in parallel failed to generate a hybridization signal (Fig. S C) . u-PA mRNA expressing cells also were increased within fibroproliferative lesions (1.0+0.5% cells positive from saline vs 29.5+±6% cells positive in lesion; P < 0.0001) but only during the fibroproliferative phase at 14 d after bleomycin injury (Fig. 5 D;  Fig. 6 ).
Intermediate filament expression of fibroproliferative lesional cells. The distribution of various intermediate filament expressing cells within fibroproliferative lesions was determined in an attempt to identify the lesional cells expressing TF, PAM-, and u-PA mRNAs. Consistent with observations in the rat (46), > 90% of the fibroproliferative lesional cells expressed vimentin, while a fraction of those cells coexpressed BM-8 (i.e., macrophages) (Fig. 7, A and D) . Both desmin, a smooth muscle cell marker, and cytokeratin, an epithelial cell marker, were absent from the interior of the fibroproliferative lesions (Fig. 7, B and C) . Desmin-expressing cells were present only in vascular and bronchial wall smooth muscle cells, while cytokeratin was detected only at the periphery of lesions in alveolar epithelial lining cells (Fig. 7, B and C) . Cytokeratin expression codistributed with cuboidal cells in alveolar septal junctions expressing high levels of TF mRNA (> 50 grains/ nucleus), supporting their type II epithelial identity. However, the 34% of lesional cells expressing TF mRNA must be a second, cytokeratin negative cell type, probably macrophages. The high level PAI-I expressing cells codistributed with vimentin in cells with large nuclei and indistinct borders strongly supporting their fibroblastic origin. The high level u-PA mRNA expressing cells codistributed with BM-8 and were commonly found within the air space in cells with round eccentric nuclei, consistent with previous reports of u-PA expression in monocytoid-macrophagic cells (47, 48) (Fig. 5 D) .
Discussion
This study compares the expression of TF and components of the fibrinolytic system with the deposition of fibrin during the course of bleomycin-induced lung injury and repair in mice. Based on previous studies showing loss of vascular integrity in bleomycin lung injury (5), it is assumed that the fibrin itself is derived from coagulation of plasma fibrinogen as it traverses the blood-air interface. As TF accounts for the major fraction of normal and bleomycin-inducible alveolar fluid procoagulant activity (17, 18, 26, (49) (50) (51) (52) , it is highly likely that TF initiates alveolar coagulation of the plasma-derived fibrinogen. However, until recently, the sites of TF production in many tissues, including lung, have remained unknown.
Chronic injury-induced induction of lung parenchymal cell TF mRNA in vivo is a novel finding. Our quantitative analysis of the TF mRNA distribution revealed an increase in TF mRNA expressing cells in fibrin-rich alveolitis areas and in fibrin-rich fibroproliferative lesions (Fig. 1) over that of saline-instilled controls, and over that of histologically normal areas from the same tissue section (Figs. 4 and 6 ). The observed increase in the percentage of TF positive cells in the fibrin-rich alveolitis regions grossly underestimates their relative lesional upregulation (four to fivefold), as the cell density of these regions increased (2.5-fold) due to lesional infiltration with TF negative neutrophils (Fig. 6 ). Taken together with the whole lung TF mRNA data (Table I) , we conclude that TF mRNA was induced preceding and coincident with the deposition of alveolar and lesional fibrin in parenchymal cells from areas within and immediately adjacent to extravascular fibrin deposits. Lesional TF mRNA producing cells codistribute with BM-8 in areas that are devoid of cytokeratin thus supporting a macrophage origin. However, the morphology of perilesional TF mRNA expressing cells will not allow for distinction between macrophages and type II alveolar epithelial cells (Figs. 4 and  7) . In our hands, epithelial cell TF mRNA expression was demonstrable in bronchial epithelium, and other investigators have observed TF production in type H alveolar epithelial cell lysates and in baboon lung tissue (46, 53, 54) . However, unequivocal confirmation of cell identities will await either double labeling or mRNA hybridization at the electron microscope level. Irrespective of the cell type, our key observation is the colocalization of TU mRNA expressing cells within fibrin-rich areas of alveolitis and fibroproliferative lesions. Lesional cell up-regulation of TF mRNA may be an important mechanism whereby local control is exerted over fibrin deposition.
Theoretically, the procoagulant action of lesional TF would support additional fibrin accumulation, if associated with local inhibition of the fibrinolytic system due to increased lesional PAI-1. As noted for TF mRNA, the actual PAI-i mRNA cell concentration within alveolitis areas (i.e., 8 d) is severalfold above that based on the quantitation of the percentage of positive lesional cells (Fig. 6) . The whole lung and tissue overlay PA/PAI-1 activity assays suggest a PAI-i -dependent suppression of u-PA parenchymal activity despite the in situ hybridization findings of lesional up-regulation of both u-PA and PAI-i mRNAs during the fibroproliferative phase (i.e., 14 d). Together with the Northern blot findings, these in situ and activity observations colocalize excess PAI-I activity and PAI-I mRNA expressing cells to sites of fibrin accumulation within areas of alveolitis (i.e., 8 d) and fibroproliferative lesions (i.e., 14 d). The apparent up-regulation of u-PA mRNA within fibroproliferative lesions is indicative of a tight regulation of lesional proteolysis on a pericellular level in vivo. Although analysis of whole lung extracts by fibrin autography is a crude measure of pericellular proteolysis, the coordinated increase in PAI-I activity (Fig. 2 B) , and suppression of u-PA activity (Fig. 2 A) together with the apparent predominance of the relatively inactive single chain u-PA form suggests that the balance of the lesional plasminogen activator activity is inhibitory. These findings strongly support the idea that cells within the fibroproliferative lesions regulate their local fibrinolytic environment, and is consistent with our hypothesis that fibroblast-derived PAM-contributes to matrix fibrin persistance in the fibroproliferative lesions.
Although PAM-mRNA expression was induced in lesions, the possibility that plasma-derived PAI-I contributes to the observed increase in total lung PAM-cannot be excluded. This is most relevant in the first week after injury when whole lung PAM-activity increased concomitant with submaximal increases in lung PAM-mRNA. However, exhaustive washing of minced tissue was performed to ensure removal of circulating plasma from the tissue before analysis, and neither PAM-protein or PAI-I mRNA were detected in pulmonary vascular endothelial cells, thus supporting a critical role for locally produced PAM-and u-PA in the total PA and PAM-activities detected.
Prior studies suggest that airspace granulation tissue is a precursor to alveolar fibrosis (1, 2, 55). Fibrin itself, as well as its soluble cleavage products are capable of modulating important processes that contribute to the formation of granulation tissue including mesenchymal cell adhesion and proliferation (9) (10) (11) (12) . Since the distribution of fibrin seen in the bleomycin model parallels that of the putative site(s) of fibroblast proliferation and matrix deposition, a plausible argument can be made that the formation of the lesions may, in part, be a result of the effects of the persistence of extravascular fibrin. The factor(s) that modulate extravascular fibrin turnover may thereby affect the ultimate extent of fibrosis after lung injury. The lesional regulation of TF and PAM-synthesis or activity (56) may be one such modulatory mechanism. The inhibition of plasminmediated enzymatic degradation of matrix fibrin and matrix glycoproteins, and plasmin-mediated activation of procollagenase and TGFO3 (57, 58) all are additional postulated mechanisms whereby inhibition of plasminogen activation by PAI-1 can alter fibrinous matrix remodeling (33, 59, 60) . Recent in vivo work has underscored the importance of TGFP for the pathogenesis of pulmonary fibrosis by demonstrating its potent matrix secretagogue activity in lung fibroblasts and by the ameliorating effect of neutralizing antibodies on bleomycin-induced pulmonary fibrosis (42, (61) (62) (63) (64) (65) (66) . Alternatively, lesional PAM-may act as a feedback loop negative regulator of TGF,6 activity, as has been suggested in vitro (58) . Future work will be directed towards defining the role of lesional fibroblast PAM-in the deposition and turnover of extracellular matrix after lung injury.
In conclusion, our analysis of bleomycin-injured murine lungs demonstrates a suppression of u-PA activity, a lesional upregulation of TF, u-PA, and PAM-mRNAs and the lesional deposition of fibrin. These data suggest that bleomycin injury results in a lesional hypercoagulable, hypofibrinolytic state which contributes to the initiation and maintenance of extravascular fibrin. Based on our data and current concepts of tissue repair, we propose that a PAI--mediated decrease in lesional fibrinolytic activity contributes to the outcome of tissue remodeling after bleomycin-induced lung injury in mice.
